Results for immunosuppressiva translation from Maltese to English

oncaspar jista' jkollu attività immunosuppressiva.
oncaspar may possess immunosuppressive activity.

idelalisib mhuwiex meqjus li għandu attività immunosuppressiva wiesgħa.
idelalisib is not considered to have broad immunosuppressive activity.

terapija immunosuppressiva kurrenti (inklużi dożi għoljin ta’ corticosteroids).
current immunosuppressive therapy (including high doses of corticosteroids).

is-sustanza attiva f’arava, leflunomide, hija mediċina immunosuppressiva.
the active substance in arava, leflunomide, is an immunosuppressant.

pazjenti li qed jieħdu kura immunosuppressiva għandhom riskju akbar li jiżviluppaw tkabbir malinn.
patients receiving immunosuppressive therapy are at increased risk of developing malignancies.

is-sustanza attiva fi nulojix, il-belatacept, hija mediċina immunosuppressiva.
the active substance in nulojix, belatacept, is an immunosuppressive medicine.

- jekk qed tieħu kura immunosuppressiva, eż. kura b’ kortikosteroidi jew kemjoterapija għall -
- are having immunosuppressive therapy, e. g. corticosteroid treatment or chemotherapy for cancer, or if

is-sustanza attiva f’cellcept, il-mikofenolat mofetil hija mediċina immunosuppressiva.
the active substance in cellcept, mycophenolate mofetil, is an immunosuppressive medicine.

il-metaboliti l-oħra għandhom biss jew attività fjakka jew l-ebda attività immunosuppressiva.
the other metabolites have only weak or no immunosuppressive activity.

waħda minn dawn biss dehret, in vitro, li għandha attività immunosuppressiva simili għal dik ta’ tacrolimus.
only one of these has been shown in vitro to have immunosuppressive activity similar to that of tacrolimus.

simulect għandu jinkiteb biss minn tobba li għandhom esperjenza b’terapija immunosuppressiva li tingħata wara trapjant ta’ organu.
simulect should be prescribed only by physicians who are experienced in the use of immunosuppressive therapy following organ transplantation.

id-doża tiddependi mill-kondizzjoni ġenerali tiegħek u fuq liema xorta ta’ kura oħra immunosuppressiva tkun qed tieħu.
your dose depends on your general condition and on which other immunosuppressive medication you are taking.

kura immunosuppressiva tista’ tinterferixxi mal-iżvilupp tar-rispons immuni mistenni (ara sezzjoni 4.4)
immunosuppressive therapy may interfere with the development of expected immune response (see section 4.4)

il-pazjenti immunokompromessi u l-pazjenti li jkunu qegħdin jieħdu kura immunosuppressiva sistemika ġew esklużi mill-provi kliniċi kkontrollati.
immunocompromised patients and patients taking systemic immunosuppressive therapy were excluded from controlled clinical trials.

jista’ jkun li f’ċerti każi titwaqqaf xi kura immunosuppressiva oħra, u b’hekk tgħaddi għal monoterapija ta’ tacrolimus.
it is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to tacrolimus monotherapy.

jista’ ma jinkisibx rispons immuni adegwat f’pazjenti li jkunu qegħdin jirċievu terapija immunosuppressiva jew f’pazjenti b’immunodefiċjenza.
in patients receiving immunosuppressive therapy or patients with immunodeficiency an adequate immune response may not be obtained.

jista’ jkun li f’ċerti każi titwaqqaf xi kura immunosuppressiva oħra, u b’hekk tgħaddi għal terapija bi tnejn ibażata fuq it- tacrolimus.
it is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to tacrolimus-based dual therapy.

neoplażmi beninni, malinni u dawk mhux speċifikati (inklużi ċesti u polipi) il- pazjenti li qed jieħdu kura immunosuppressiva għandhom riskju akbar li jiżviluppaw tkabbir malinn.
patients receiving immunosuppressive therapy are at increased risk of developing malignancies.

11 • terapija immunosuppressiva (inkluż corticosteroids f 'doża kbira); madankollu, m' hemmx kontra- indikazzjonijiet għall- użu ta' zostavax f' individwi li qegħdin jieħdu corticosteroids f' parti mill- ġisem/ b’ inalatur jew corticosteroids sistematiċi ta 'doża żgħira jew f' pazjenti li qegħdin jirċievu corticosteroids bħala terapija ta' sostituzzjoni, eż., għal insuffiċjenza adrenali. • tuberkolożi attiva mhux trattata. • tqala (ara sezzjonijiet 4. 4 u 4. 6).
11 • primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukaemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to hiv/ aids; cellular immune deficiencies. • immunosuppressive therapy (including high-dose corticosteroids); however, zostavax is not contraindicated for use in individuals who are receiving topical/ inhaled corticosteroids or low-dose systemic corticosteroids or in patients who are receiving corticosteroids as replacement therapy, e. g., for adrenal insufficiency. • active untreated tuberculosis. • pregnancy (see sections 4.4 and 4.6).